Havrix

Havrix is an inactivated hepatitis A vaccine whose active ingredients are hepatitis A virus (inactivated) and algeldrate, provided as an injectable preparation (strength not specified). It is authorized for use in the European Union and is prescribed by healthcare professionals to induce active immunity against hepatitis A infection. The vaccine is administered by intramuscular or subcutaneous injection. The formulation is stored in a sterile vial and requires refrigeration before administration.

Havrix is indicated for the prevention of hepatitis A infection in individuals who have not been previously immunized or who require booster protection.

- Primary prophylaxis for adults and children aged 12 months and older who are at risk of hepatitis A exposure. - Pre‑travel vaccination for persons traveling to regions where hepatitis A is endemic. - Post‑exposure prophylaxis for close contacts of confirmed hepatitis A cases when vaccine is administered within two weeks of exposure. - Booster dosing for individuals who received a complete hepatitis A vaccine series at least 15 years earlier. - Immunization of individuals with chronic liver disease to reduce the risk of severe hepatitis A complications.

The safety profile of Havrix reflects the typical reactions observed with inactivated viral vaccines, most of which are mild and transient and usually resolve without intervention.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever. - Headache or mild fatigue. - Nausea or transient gastrointestinal discomfort. - Mild muscle aches at or near the injection site. - Transient rash elsewhere on the body. - Mild fever lasting less than 24 hours.

Serious: - Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, swelling of the face or throat, and rapid heartbeat. - Neurologic events such as Guillain‑Barré syndrome, although these are rare. - Severe thrombocytopenia presenting with easy bruising or bleeding.

Precautions for Havrix focus on patient history, immune status, and proper administration techniques to ensure safety and effectiveness.

- Verify that the individual has no known severe allergy to any vaccine component, including algeldrate. - Defer vaccination in persons with acute moderate or severe illness until recovery. - Assess immune competence; immunocompromised patients may have a reduced antibody response. - Avoid intramuscular injection into the buttock; use the deltoid or anterolateral thigh for appropriate age groups. - Observe the patient for at least 15 minutes after injection to monitor for immediate allergic reactions. - Store the vaccine according to the manufacturer’s instructions, typically refrigerated between 2 °C and 8 °C, and protect from freezing.

Havrix does not have many documented drug‑drug interactions, but certain substances and conditions may influence its administration or immune response.

Avoid: - Live viral vaccines administered within four weeks before or after Havrix should be avoided to prevent potential interference with immune response. - Immunoglobulin or blood products given within two weeks of vaccination may reduce the effectiveness of the hepatitis A vaccine.

Use with caution: - Antipyretics such as acetaminophen or ibuprofen may be used to manage mild post‑vaccination symptoms, but routine prophylactic use before vaccination is not recommended. - Patients receiving immunosuppressive therapy (e.g., corticosteroids, biologics) may have a diminished antibody response and should be evaluated for adequate protection. - Pregnant or breastfeeding individuals should discuss vaccination with their healthcare provider, as safety data are limited.